Thrombocytosis (platelets > 450 G/L)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Platelets > 450 G/L without severity signs: initial tests
Laboratory tests
- FBC with blood film
- Serum ferritin
- CRP
- Serum creatinineif needednon-French guidelineThrombocytosis without an obvious reactive cause on history and examination: these tests appear in the work-ups of the British primary care pathways [2,3]. A raised alkaline phosphatase with thrombocytosis further increases the probability of cancer [2].
- ASTif needednon-French guidelineThrombocytosis without an obvious reactive cause on history and examination: these tests appear in the work-ups of the British primary care pathways [2,3]. A raised alkaline phosphatase with thrombocytosis further increases the probability of cancer [2].
- ALTif needednon-French guidelineThrombocytosis without an obvious reactive cause on history and examination: these tests appear in the work-ups of the British primary care pathways [2,3]. A raised alkaline phosphatase with thrombocytosis further increases the probability of cancer [2].
- GGTif needednon-French guidelineThrombocytosis without an obvious reactive cause on history and examination: these tests appear in the work-ups of the British primary care pathways [2,3]. A raised alkaline phosphatase with thrombocytosis further increases the probability of cancer [2].
- Alkaline phosphataseif needednon-French guidelineThrombocytosis without an obvious reactive cause on history and examination: these tests appear in the work-ups of the British primary care pathways [2,3]. A raised alkaline phosphatase with thrombocytosis further increases the probability of cancer [2].
- LDHif needednon-French guidelineThrombocytosis without an obvious reactive cause on history and examination: these tests appear in the work-ups of the British primary care pathways [2,3]. A raised alkaline phosphatase with thrombocytosis further increases the probability of cancer [2].
- Serum calcium (if no obvious cause)if needednon-French guidelineUnexplained thrombocytosis: serum calcium is among the tests suggested by the York pathway [3].
Imaging
- Chest X-ray (aged 40 or over, unexplained thrombocytosis)if needednon-French guidelinePatient aged 40 or over with thrombocytosis: NICE proposes considering an urgent chest X-ray to look for lung cancer [4]; the Lothian pathway requests it when no symptom points to another cancer [2].
In 4 to 6 weeks
- FBC (repeat)
Persistent unexplained thrombocytosis: before referral
Laboratory tests
- FBC with blood film
- Serum ferritinif needednon-French guidelineHaematology advice for persistent thrombocytosis presupposes a normal CRP and ferritin [3].
- CRPif needednon-French guidelineHaematology advice for persistent thrombocytosis presupposes a normal CRP and ferritin [3].
- JAK2 V617F mutation (not in the French laboratory fee schedule: not reimbursed in community practice; preferably by the haematologist)if needednon-French guidelinePersistent thrombocytosis without a reactive cause, when referring for suspected myeloproliferative neoplasm: the GP can send the JAK2 test with the request for advice [3].
- CALR and MPL mutations (if JAK2 negative; not in the French laboratory fee schedule, by the haematologist)if needednon-French guidelineJAK2 testing negative in a patient suspected of essential thrombocythaemia: CALR and MPL are the two other driver mutations of the WHO criterion [12]. Specialist test, to be left to the haematologist.
- BCR-ABL transcript (to rule out chronic myeloid leukaemia; preferably at the haematologist's initiative)if needednon-French guidelineThe German DGHO (2023) looks for it at the same time as JAK2, CALR and MPL [13]; the WHO criteria require exclusion of BCR-ABL1-positive chronic myeloid leukaemia [12]. NABM procedure 1035 covers the diagnosis and follow-up of this leukaemia [9].
Severity sign: urgent haematology advice
- Platelets > 1000 G/L, recent arterial or venous thrombosis, neurological signs or bleeding: rapid haematology opinion, possibly the same day.
Sources (17)
- Bailey SE, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract. 2017;67(659):e405-e413.
- NHS Lothian. RefHelp : Thrombocytosis (haematology referral guideline), version du 2 décembre 2025.
- Humber and North Yorkshire Policy and Pathway Repository (York). Thrombocytosis pathway. Dr A. Whittle, hématologue ; modifié le 16 septembre 2025 (révision prévue en 2027).
- National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NG12). Publiée le 23 juin 2015, mise à jour le 15 avril 2026 : recommandations 1.1.3, 1.2.3, 1.2.9 et 1.5.13.
- Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245(3):295-300.
- Liautard C, Nunes AM, Vial T, et al. Low-molecular-weight heparins and thrombocytosis. Ann Pharmacother. 2002;36(9):1351-4.
- Frye JL, Thompson DF. Drug-induced thrombocytosis. J Clin Pharm Ther. 1993;18(1):45-8.
- Clarke C, Hamilton W, Price S, Bailey SER. Association of non-malignant diseases with thrombocytosis: a prospective cohort study in general practice. Br J Gen Pract. 2020;70(701):e852-e857.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1213 (ferritine) ; absence d'acte JAK2, CALR et MPL.
- Vora AJ, Lilleyman JS. Secondary thrombocytosis. Arch Dis Child. 1993;68(1):88-90.
- Williams PM, Williams AL. Thrombocytosis: Rapid Evidence Review. Am Fam Physician. 2026;113(4):332-338.
- Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.
- Petrides PE, Baerlocher GM, Döhner K, Gisslinger H, Grießhammer M, Koschmieder S, Schwaab J, et al. Essentielle (oder primäre) Thrombozythämie (ET). Leitlinie Onkopedia (DGHO), décembre 2023.
- Agence du numérique en santé. Terminologie LAHN (liste des actes innovants hors nomenclature de biologie et d'anatomopathologie), version 2026-04 : codes N417 et N455.
- Buss DH, Cashell AW, O'Connor ML, Richards F 2nd, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96(3):247-53.
- Humber and North Yorkshire Policy and Pathway Repository (York). Thrombocytosis pathway. (liste des causes)
- Frye JL, Thompson DF. Drug-induced thrombocytosis. J Clin Pharm Ther. 1993;18(1):45-8. (résumé)